Evaluation of temporal changes in cardiovascular biomarker concentrations improves risk prediction in an elderly population from the community

Clinical Chemistry

Volumn 62, Issue 3, 2016, Pages 485-493

  Eggers, Kai M ^a   Kempf, Tibor ^a,b   Larsson, Anders ^a   Lindahl, Bertil ^a   Venge, Per ^a   Wallentin, Lars ^a   Wollert, Kai C ^a,b   Lind, Lars ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; CARDIOVASCULAR BIOMARKER; GALECTIN 3; GROWTH DIFFERENTIATION FACTOR 15; PROADRENOMEDULLIN; SOLUBLE ST2; TROPONIN I; UNCLASSIFIED DRUG;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMMUNITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MORTALITY; OUTCOME ASSESSMENT; PREDICTION; PREDICTOR VARIABLE; PROGNOSIS; BLOOD; CARDIOVASCULAR DISEASES; PATHOPHYSIOLOGY; PREDICTIVE VALUE; REGRESSION ANALYSIS; TIME FACTOR;

AGED; BIOMARKERS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REGRESSION ANALYSIS; TIME FACTORS;

EID: 84959283705     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2015.246876     Document Type: Article

References (36)

1. Eggers KM, Venge P. Utility of B-type natriuretic peptides and cardiac troponins for population screening regarding cardiac abnormalities. Pathology 2012;44:129-38.
2. Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engström G, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 2009;302:49-57.
3. Wang TJ, Wollert KC, Larson MG, Coglianese E, McCabe EL, Cheng S, et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation 2012;126:1596-604.
4. Funke-Kaiser A, Havulinna AS, Zeller T, Appelbaum S, Jousilahti P, Vartiainen E, et al. Predictive value of midregional pro-adrenomedullin compared to natriuretic peptides for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort. Ann Med 2014;46:155-62.
5. Rohatgi A, Patel P, Das SR, Ayers CR, Khera A, Martinez-Rumayor A, et al. Association of growth differentiation factor-15 with coronary atherosclerosis and mortality in a young, multiethnic population: observations from the Dallas Heart Study. Clin Chem 2012;58:172-82.
6. Chen LQ, de Lemos JA, Das SR, Ayers CR, Rohatgi A. Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: the Dallas Heart Study. Clin Chem 2013;59:536-46.
7. Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 2012;60:1249-56.
8. Jagodzinski A, Havulinna AS, Appelbaum S, Zeller T, Jousilahti P, Skytte-Johanssen S, et al. Predictive value of galectin-3 for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort. Int J Cardiol 2015;192:33-9.
9. Kato J, Tsuruda T, Kita T, Kitamura K, Eto T. Adrenomedullin: a protective factor for blood vessels. Arterioscler Thromb Vasc Biol 2005;25:2480-7.
10. Wollert KC, Kempf T. Growth differentiation factor 15 in heart failure: an update. Curr Heart Fail Rep 2012;9:337-45.
11. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008;7:827-40.
12. de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009;11:811-7.
13. Eggers KM, Venge P, Lind L. Prognostic usefulness of the change in N-terminal pro B-type natriuretic peptide levels to predict mortality in a single community cohort >70 years of age. Am J Cardiol 2013;111:131-6.
14. Eggers KM, Venge P, Lindahl B, Lind L. Cardiac troponin I levels measured with a high-sensitive assay increase over time and are strong predictors of mortality in an elderly population. J Am Coll Cardiol 2013;61:1906-13.
15. Eggers KM, Kempf T, Wallentin L, Wollert KC, Lind L. Change in growth differentiation factor 15 concentrations over time independently predicts mortality in community-dwelling elderly individuals. Clin Chem 2013;59:1091-8.
16. Eggers KM, Venge P, Lindahl B, Lind L. Associations of mid-regional pro-adrenomedullin levels to cardiovascular and metabolic abnormalities, and mortality in an elderly population from the community. Int J Cardiol 2013;168:3537-42.
17. Lind L, Fors N, Hall J, Marttala K, Stenborg A. A comparison of three different methods to evaluate endothelium-dependent vasodilatation in the elderly. The Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Arterioscler Thromb Vasc Biol 2005;25:2368-75.
18. Kempf T, Horn-Wichmann R, Brabant G, Peter T, Allhoff T, Klein G, et al. Circulating concentrations of growthdifferentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clin Chem 2007;53:284-91.
19. Levey AS, Greene T, Kusek JW, Beck GJ; MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000;11:155A.
20. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-72.
21. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
22. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11-21.
23. D'Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743-53.
24. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr 1974;19:716-23.
25. Brown DA, Moore J, Johnen H, Smeets TJ, Bauskin AR, Kuffner T, et al. Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: a potential marker of erosive joint destruction. Arthritis Rheum 2007;56:753-64.
26. Mimeault M, Batra SK. Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J Cell Physiol 2010;224:626-35.
27. Wiklund FE, Bennet AM, Magnusson PK, Eriksson UK, Lindmark F, Wu L, et al. Macrophage inhibitory cytokine-1 (MIC-1/GDF15): a new marker of all-cause mortality. Aging Cell 2010;9:1057-64.
28. Hughes MF, Appelbaum S, Havulinna AS, Jagodzinski A, Zeller T, Kee F, et al. ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality. Heart 2014;100:1715-21.
29. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009;119:2408-16.
30. Erratum in: Circulation 2009;119:e606.
31. Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008;358:2107-16.
32. Glick D, DeFilippi CR, Christenson R, Gottdiener JS, Seliger SL. Long-term trajectory of two unique cardiac biomarkers and subsequent left ventricular structural pathology and risk of incident heart failure in community-dwelling older adults at low baseline risk. JACC Heart Fail 2013;1:353-60.
33. deFilippi CR, Christenson RH, Gottdiener JS, Kop WJ, Seliger SL. Dynamic cardiovascular risk assessment in elderly people. The role of repeated N-terminal pro-Btype natriuretic peptide testing. J Am Coll Cardiol 2010;55:441-50.
34. McEvoy JW, Lazo M, Chen Y, Shen L, Nambi V, Hoogeveen RC, et al. Patterns and determinants of temporal change in high-sensitivity cardiac troponin-T: The Atherosclerosis Risk in Communities Cohort Study. Int J Cardiol 2015;187:651-7.
35. Wu AH. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. Am Heart J 2006;152:828-34.
36. Nordenskjöld AM, Ahlström H, Eggers KM, Fröbert O, Jaffe AS, Venge P, Lindahl B. Short- and long-term individual variation in cardiac troponin in patients with stable coronary artery disease. Clin Chem 2013;59:401-9.